Neoplasm Recurrence, Local

The grounded definition attributes local recurrence to microscopic cells from the original neoplasm that survive treatment and later become visible again at the same site. The supplied literature also links recurrence more broadly to treatment resistance and residual disease. No more specific etiologic cause is supported across the provided materials.

The recurrence process is associated with residual tumor cells that evade therapeutic intervention and later re-expand. The grounding also points to mechanisms such as drug resistance, tumor microenvironment effects, cell proliferation, signal transduction, gene expression regulation, molecular evolution, and DNA mismatch repair as relevant to recurrence biology. In some cancers, recurrent disease is described as arising from resistant, stem-like, or genomically reprogrammed cells that initiate regrowth.

The supplied grounding supports treatment resistance, residual microscopic disease after therapy, and tumor heterogeneity as factors associated with recurrence. It also indicates that molecular evolution and resistant cell populations can contribute to relapse. No general patient-level risk factors are supported by the provided materials.

The grounding supports management at the level of surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy depending on the underlying cancer. Co-studied drug classes and agents include platinum chemotherapy, fluorouracil, taxanes, immune checkpoint inhibitors such as pembrolizumab, nivolumab, dostarlimab, durvalumab, and ipilimumab, antibody-drug conjugates such as tisotumab vedotin, anti-VEGF therapy such as bevacizumab, and targeted therapy such as osimertinib. The literature also mentions surveillance for relapse and subsequent treatment in some cancers, but does not support a single universal regimen for local recurrence.